Title A Phase I, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SG1-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Principal Investigator Elizabeth Griffiths, MD
Study Number 197411
Summary The specific purpose of th study is to find out whether SGI-110 given subcutaneously (under the skin) is safe and effective as a treatment for MDS or AML.
- See Clinicaltrials.gov listing for current Eligibility criteria.